Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | NVP-TNKS656 + Triciribine |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
NVP-TNKS656 | NVP656 | Tankyrase Inhibitor 11 | NVP-TNKS656 is a small molecule that inhibits Tankyrase, resulting in decreased Beta-catenin signaling, and potentially leading to reduced tumor growth (PMID: 26224873, PMID: 30944457, PMID: 31897238). | |
Triciribine | VQD-002|API-2 | Akt Inhibitor (Pan) 21 | Triciribine (API-2) is a purine analog that inhibits DNA synthesis, and blocks Akt phosphorylation, which may reduce proliferation and promote apoptosis in cancer cells (PMID: 21636709, PMID: 19422047). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CTNNB1 over exp | colon cancer | predicted - sensitive | NVP-TNKS656 + Triciribine | Preclinical - Pdx | Actionable | In a preclinical study, the combination of NVP-TNKS656 and Triciribine (API-2) inhibited tumor growth in Triciribine (API-2)-resistant patient-derived xenograft (PDX) models of colon cancer with high nuclear CTNNB1 (Beta-catenin) levels (PMID: 26224873). | 26224873 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|